GABLOFEN Drug Insight and Market Forecast - 2032

“"GABLOFEN Drug Insight and Market Forecast - 2032" report provides comprehensive insights about GABLOFEN for spasticity in the seven major markets. A detailed picture of the GABLOFEN for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the GABLOFEN for spasticity. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GABLOFEN market forecast analysis for spasticity in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in spasticity.

Drug Summary:

GABLOFEN (baclofen injection) is a gamma-aminobutyric acid (GABA-ergic) agonist for managing severe spasticity of cerebral or spinal origin in adult and pediatric patients aged 4 years and above. GABLOFEN is reserved for patients unresponsive to oral baclofen therapy or those who experience intolerable central nervous system side effects at effective doses. Patients are advised to first respond to a screening dose of intrathecal baclofen before consideration for long-term infusion via an implantable pump. For spasticity due to traumatic brain injury, consider GABLOFEN therapy only after 1 year of the injury.

Mechanism of action

The precise mechanism of action of baclofen as a muscle relaxant and an antispasticity agent is not fully understood. Baclofen inhibits monosynaptic and polysynaptic reflexes at the spinal level, possibly by decreasing excitatory neurotransmitter release from primary afferent terminals. However, actions at supraspinal sites may also occur and contribute to its clinical effect. Baclofen is a structural analog of the inhibitory neurotransmitter GABA and may exert its effects by stimulating the GABAB receptor subtype.

When introduced directly into the intrathecal space, baclofen permits effective CSF concentrations with resultant plasma concentrations 100 times less than those with oral administration. Baclofen has been shown to have general CNS depressant properties in people and animals, as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the GABLOFEN description, mechanism of action, dosage and administration, research and development activities in spasticity.
• Elaborated details on GABLOFEN regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GABLOFEN research and development activities in spasticity across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around GABLOFEN.
• The report contains forecasted sales of GABLOFEN for spasticity till 2032.
• Comprehensive coverage of the late-stage emerging therapies for spasticity.
• The report also features the SWOT analysis with analyst views for GABLOFEN in spasticity.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GABLOFEN Analytical Perspective by DelveInsight

• In-depth GABLOFEN Market Assessment

This report provides a detailed market assessment of GABLOFEN for spasticity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• GABLOFEN Clinical Assessment

The report provides the clinical trials information of GABLOFEN for spasticity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for spasticity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GABLOFEN dominance.
• Other emerging products for spasticity are expected to give tough market competition to GABLOFEN and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GABLOFEN in spasticity.
• Our in-depth analysis of the forecasted sales data of GABLOFEN from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GABLOFEN in spasticity.

Key Questions

• What is the product type, route of administration and mechanism of action of GABLOFEN?
• What is the clinical trial status of the study related to GABLOFEN in spasticity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GABLOFEN development?
• What are the key designations that have been granted to GABLOFEN for spasticity?
• What is the forecasted market scenario of GABLOFEN for spasticity?
• What are the forecasted sales of GABLOFEN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to GABLOFEN for spasticity?
• Which are the late-stage emerging therapies under development for the treatment of spasticity?